Molcure is a high-speed, high-quality, high-variation antibody screening & design system combining biology, automation and bioinformatics
Molcure is antibody and Peptide drug-focused biopharmaceutical company whose passionate associates are dedicated to improving the lives of patients by developing and providing more effective therapeutics and supportive care products. Molcure represents high quality antibody and target discovery. With cutting edge technology in-house, Molcure is the partner of choice for therapeutic antibody discovery. At Molcure they combine a deep knowledge of NGS, bioinformatics and antibody biology with automated discovery system. The antibody discovery platform Abtracer delivers superior functional antibodies. Their technology is validated through a number of partnerships. They are seeking new partnership opportunities.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 18, 2021 | Series C | ¥800M | 1 | JAFCO Group | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
JAFCO Group | Yes | Series C |